Differential reactivation of fetal/neonatal genes in mouse liver tumors induced in cirrhotic and non-cirrhotic conditions

Cancer Science

Volumn 106, Issue 8, 2015, Pages 972-981

  Chen, Xi ^a   Yamamoto, Masahiro ^a   Fujii, Kiyonaga ^a   Nagahama, Yasuharu ^a   Ooshio, Takako ^a   Xin, Bing ^a   Okada, Yoko ^a   Furukawa, Hiroyuki ^a   Nishikawa, Yuji ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Hepatocellular carcinoma; Insulin like growth factor 2; Liver cirrhosis; mRNA expression; Trefoil factor 3

Indexed keywords

CARBON TETRACHLORIDE; COMPLEMENTARY DNA; DIETHYLNITROSAMINE; MESSENGER RNA; SOMATOMEDIN B; TREFOIL FACTOR 3; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA MICROARRAY; FETUS; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; C3H MOUSE; C57BL MOUSE; COMPLICATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; POLYMERASE CHAIN REACTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION;

EID: 84939257015     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12700     Document Type: Article

References (33)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
2. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer 2013; 2: 367-83.
3. Liu TC, Vachharajani N, Chapman WC, Brunt EM. Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. Mod Pathol 2014; 27: 420-32.
4. Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010; 12: 509-22.
5. Vesselinovitch SD. Infant mouse as a sensitive bioassay system for carcinogenicity of N-nitroso compounds. IARC Sci Publ 1980; 31: 645-55.
6. Wang Y, Cui F, Lv Y et al. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology 2004; 39: 318-24.
7. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005; 24: 1809-19.
8. Calvisi DF, Factor VM, Ladu S, Conner EA, Thorgeirsson SS. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004; 126: 1374-86.
9. Edwards JE. Hepatomas in mice induced with carbon tetrachloride. J Natl Cancer Inst 1941; 2: 197-9.
10. Gothoskar SV, Talwalkar GV, Bhide SV. Tumorigenic effect of thioacetamide in Swiss strain mice. Br J Cancer 1970; 24: 498-503.
11. Andervont HB. Studies on the occurrence of spontaneous hepatomas in mice of strains C3H and CBA. J Natl Cancer Inst 1950; 11: 581-92.
12. Leighton PA, Saam JR, Ingram RS, Stewart CL, Tilghman SM. An enhancer deletion affects both H19 and Igf2 expression. Genes Dev 1995; 9: 2079-89.
13. Vernucci M, Cerrato F, Besnard N et al. The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis. Oncogene 2000; 19: 6376-85.
14. Lederer M, Bley N, Schleifer C, Huttelmaier S. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Semin Cancer Biol 2014; 29C: 3-12.
15. Sell S, Becker FF, Leffert HL, Watabe L. Expression of an oncodevelopmental gene product (alpha-fetoprotein) during fetal development and adult oncogenesis. Cancer Res 1976; 36: 4239-49.
16. Nordin M, Bergman D, Halje M, Engstrom W, Ward A. Epigenetic regulation of the Igf2/H19 gene cluster. Cell Prolif 2014; 47: 189-99.
17. Grozdanov PN, Yovchev MI, Dabeva MD. The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest 2006; 86: 1272-84.
18. Finkielstain GP, Forcinito P, Lui JC et al. An extensive genetic program occurring during postnatal growth in multiple tissues. Endocrinology 2009; 150: 1791-800.
19. Okada H, Kimura MT, Tan D et al. Frequent trefoil factor 3 (TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas. Int J Oncol 2005; 26: 369-77.
20. Sun Q, Zhang Y, Liu F, Zhao X, Yang X. Identification of candidate biomarkers for hepatocellular carcinoma through pre-cancerous expression analysis in an HBx transgenic mouse. Cancer Biol Ther 2007; 6: 1532-8.
21. Hoffmann W. Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cell Mol Life Sci 2005; 62: 2932-8.
22. Sohda T, Yun K, Iwata K, Soejima H, Okumura M. Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 1996; 75: 307-11.
23. Sohda T, Iwata K, Soejima H, Kamimura S, Shijo H, Yun K. In situ detection of insulin-like growth factor II (IGF2) and H19 gene expression in hepatocellular carcinoma. J Hum Genet 1998; 43: 49-53.
24. Ariel I, Miao HQ, Ji XR et al. Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol 1998; 51: 21-5.
25. Boyault S, Rickman DS, de Reynies A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45: 42-52.
26. Yamamoto Y, Nishikawa Y, Tokairin T, Omori Y, Enomoto K. Increased expression of H19 non-coding mRNA follows hepatocyte proliferation in the rat and mouse. J Hepatol 2004; 40: 808-14.
27. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005.
28. Kato T, Miyamoto M, Date T et al. Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice. Cancer Sci 2003; 94: 679-85.
29. Saenz Robles MT, Pipas JM. T antigen transgenic mouse models. Semin Cancer Biol 2009; 19: 229-35.
30. Schirmacher P, Held WA, Yang D, Chisari FV, Rustum Y, Rogler CE. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 1992; 52: 2549-56.
31. Stegmaier P, Voss N, Meier T, Kel A, Wingender E, Borlak J. Advanced computational biology methods identify molecular switches for malignancy in an EGF mouse model of liver cancer. PLoS One 2011; 6: e17738.
32. Niwa T, Ushijima T. Induction of epigenetic alterations by chronic inflammation and its significance on carcinogenesis. Adv Genet 2010; 71: 41-56.
33. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014; 54: 716-27.